Synthetic biology in the clinic: engineering vaccines, diagnostics, and therapeutics
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
SUMMARY Synthetic biology is a design-driven discipline centered on engineering novel biological functions through the discovery, characterization, and repurposing of molecular parts. Several synthetic biological solutions to critical biomedical problems are on the verge of widespread adoption and demonstrate the burgeoning maturation of the field. Here, we highlight applications of synthetic biology in vaccine development, molecular diagnostics, and cell-based therapeutics, emphasizing technologies approved for clinical use or in active clinical trials. We conclude by drawing attention to recent innovations in synthetic biology that are likely to have a significant impact on future applications in biomedicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity
Chen, J. S., Ma, E., Harrington, L. B., Da Costa, M., Tian, X., Palefsky, J. M., & Doudna, J. A. (2018) · Science · doi:10.1126/science.aar6245 · Cited by 4,507 · cited 9×
“As mentioned above, Cas12a uses a crRNA to guide binding and in cis cutting of target dsDNA (Chen et al., 2018).”
BackgroundMethodInfluentialAn mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Warren, L., Manos, P. D., Ahfeldt, T., Loh, Y.-H., Li, H., Lau, F., Ebina, W., Mandal, P. K., Smith, Z. D., Meissner, A., et al. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.08.012 · Cited by 2,662
Self-citationCreation of a Bacterial Cell Controlled by a Chemically Synthesized Genome
Gibson, D. G., Glass, J. I., Lartigue, C., Noskov, V. N., Chuang, R.-Y., Algire, M. A., Benders, G. A., Montague, M. G., Ma, L., Moodie, M. M., et al. (2010) · Science · doi:10.1126/science.1190719 · Cited by 2,638
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615 · cited 1×
“BNT162b1 and BNT162b2 induced similar levels of neutralizing antibodies, but two injections were essential to generate strong antibody responses, and BNT162b2 produced significantly fewer systemic side effects, especially in older patients (65–85 years) (Walsh et al., 2020).”
BackgroundCOVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L. M., Vormehr, M., Baum, A., Pascal, K., Quandt, J., Maurus, D., et al. (2020) · Nature · doi:10.1038/s41586-020-2814-7 · Cited by 1,977 · cited 2×
“…T4 fibritin foldon domain, and early studies (Mulligan et al., 2020) showed that two injections increased SARS-CoV-2 neutralizing immunoglobulin G (IgG) titers from 0.7- to 3.5-fold relative to COVID-19 convalescent plasma and expanded antigen-specific CD8+ and CD4+ T cells (Sahin et al., 2020).”
BackgroundInfluentialKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930 · cited 2×
“…5-methoxyuridine, or 5-methylcytidine to create mRNAs that evade innate immune effectors, such as protein kinase R, Tolllike receptors 3, 7, and 8, and retinoic acid-inducible gene I, which help detect exogenous RNAs (Karikó et al., 2008; Andries et al., 2015; Warren et al., 2010).”
BackgroundPrecision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile
Buffie, C. G., Bucci, V., Stein, R. R., McKenney, P. T., Ling, L., Gobourne, A., No, D., Liu, H., Kinnebrew, M., Viale, A., et al. (2015) · Nature · doi:10.1038/nature13828 · Cited by 1,872
Dysbiosis of the gut microbiota in disease
Carding, S., Verbeke, K., Vipond, D. T., Corfe, B. M., & Owen, L. J. (2015) · Microbial Ecology in Health & Disease · doi:10.3402/mehd.v26.26191 · Cited by 1,710
Mulligan, M. J., Lyke, K. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Raabe, V., Bailey, R., Swanson, K. A., et al. (2020) · doi:10.1101/2020.06.30.20142570 · Cited by 1,569
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523 · cited 1×
“Two vaccine injections generated antibody levels similar to the upper half of levels detected in coronavirus disease 2019 (COVID-19) convalescent serum (Jackson et al., 2020a; Anderson et al., 2020).”
BackgroundInducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
Di Stasi, A., Tey, S.-K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., Straathof, K., Liu, E., Durett, A. G., Grilley, B., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106152 · Cited by 1,512
Seow, J., Graham, C., Merrick, B., Acors, S., Pickering, S., Steel, K. J. A., Hemmings, O., O’Byrne, A., Kouphou, N., Galao, R. P., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00813-8 · Cited by 1,419 · cited 2×
“The durability of immunity is unclear since titers of SARS-CoV-2-specific IgG vary widely between individuals after natural infection, with some reports of waning response within 3 months (Seow et al., 2020) and others reporting unchanged titers to at least 4 months after infection (Gudbjartsson et al.”
BackgroundUnified rational protein engineering with sequence-based deep representation learning
Alley, E. C., Khimulya, G., Biswas, S., AlQuraishi, M., & Church, G. M. (2019) · Nature Methods · doi:10.1038/s41592-019-0598-1 · Cited by 1,131 · cited 1×
“, 2020) or creating (Alley et al., 2019) novel biological components; characterizing, classifying, and improving their performance (Angenent-Mari et al.”
BackgroundDelivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery
Kowalski, P. S., Rudra, A., Miao, L., & Anderson, D. G. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.012 · Cited by 1,127 · cited 1×
“Synthetic biology and biochemical approaches have been used to increase the intracellular stability of vaccine RNAs, reduce cytotoxicity, and enhance protein production (Jackson et al., 2020b; Pardi et al., 2020; Kowalski et al., 2019).”
MethodHumoral Immune Response to SARS-CoV-2 in Iceland
Gudbjartsson, D. F., Norddahl, G. L., Melsted, P., Gunnarsdottir, K., Holm, H., Eythorsson, E., Arnthorsson, A. O., Helgason, D., Bjarnadottir, K., Ingvarsson, R. F., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2026116 · Cited by 903 · cited 1×
“, 2020) and others reporting unchanged titers to at least 4 months after infection (Gudbjartsson et al., 2020).”
BackgroundKarikó, K., Muramatsu, H., Ludwig, J., & Weissman, D. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr695 · Cited by 898 · cited 1×
“Biochemical removal of undesirable dsRNA contaminants generated during in vitro transcription of RNAs decreases innate immune activation and translational suppression (Karikó et al., 2011).”
BackgroundVirus attenuation by genome-scale changes in codon pair bias
Coleman, J. R., Papamichail, D., Skiena, S., Futcher, B., Wimmer, E., & Mueller, S. (2008) · Science · doi:10.1126/science.1155761 · Cited by 715 · cited 1×
“Subsequently, deoptimized pairs of codons using hundreds of synonymous mutations in poliovirus resulted in 1,000-fold attenuation, but maintained protection against paralysis and death in murine models (Coleman et al., 2008).”
BackgroundAndries, O., Mc Cafferty, S., De Smedt, S. C., Weiss, R., Sanders, N. N., & Kitada, T. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.051 · Cited by 701 · cited 2×
“…5-methoxyuridine, or 5-methylcytidine to create mRNAs that evade innate immune effectors, such as protein kinase R, Tolllike receptors 3, 7, and 8, and retinoic acid-inducible gene I, which help detect exogenous RNAs (Karikó et al., 2008; Andries et al., 2015; Warren et al., 2010).”
BackgroundMyD88: a central player in innate immune signaling
Deguine, J., & Barton, G. M. (2014) · F1000Prime Reports · doi:10.12703/p6-97 · Cited by 692
mRNA vaccine delivery using lipid nanoparticles
Reichmuth, A. M., Oberli, M. A., Jaklenec, A., Langer, R., & Blankschtein, D. (2016) · Therapeutic Delivery · doi:10.4155/tde-2016-0006 · Cited by 624
An ingestible bacterial-electronic system to monitor gastrointestinal health
Mimee, M., Nadeau, P., Hayward, A., Carim, S., Flanagan, S., Jerger, L., Collins, J., McDonnell, S., Swartwout, R., Citorik, R. J., et al. (2018) · Science · doi:10.1126/science.aas9315 · Cited by 606 · cited 1×
“These techniques can be used alongside rational design to successfully implement complex biological systems (Mimee et al., 2018; Schmidts et al., 2019).”
BackgroundSelf-citationIsabella, V. M., Ha, B. N., Castillo, M. J., Lubkowicz, D. J., Rowe, S. E., Millet, Y. A., Anderson, C. L., Li, N., Fisher, A. B., West, K. A., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4222 · Cited by 605 · cited 2×
“SYNB1618 has demonstrated specific conversion of Phe to TCA and subsequently hippurate (HA) in mice (Isabella et al., 2018) and in a phase I/IIa trial (NCT03516487) of PKU patients and healthy controls (Synlogic, 2019).”
BackgroundImmunogenicity of a DNA vaccine candidate for COVID-19
Smith, T. R. F., Patel, A., Ramos, S., Elwood, D., Zhu, X., Yan, J., Gary, E. N., Walker, S. N., Schultheis, K., Purwar, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16505-0 · Cited by 601
Ishino, Y., Krupovic, M., & Forterre, P. (2018) · Journal of Bacteriology · doi:10.1128/jb.00580-17 · Cited by 558
Redesigning an FKBP–ligand interface to generate chemical dimerizers with novel specificity
Clackson, T., Yang, W., Rozamus, L. W., Hatada, M., Amara, J. F., Rollins, C. T., Stevenson, L. F., Magari, S. R., Wood, S. A., Courage, N. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.18.10437 · Cited by 558
Thess, A., Grund, S., Mui, B. L., Hope, M. J., Baumhof, P., Fotin-Mleczek, M., & Schlake, T. (2015) · Molecular Therapy · doi:10.1038/mt.2015.103 · Cited by 556 · cited 2×
“This significantly enhances protein production through unclear mechanisms when matched to optimized 50 and 30 UTRs (Thess et al., 2015).”
BackgroundmRNA structure regulates protein expression through changes in functional half-life
Mauger, D. M., Cabral, B. J., Presnyak, V., Su, S. V., Reid, D. W., Goodman, B., Link, K., Khatwani, N., Reynders, J., Moore, M. J., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1908052116 · Cited by 555 · cited 1×
“Engineering low secondary structure in the 50 UTR and first 30 nt of a coding region, but adding a high secondary structure region after these regions also improves mRNA translation (Mauger et al., 2019).”
BackgroundRecent advances in mRNA vaccine technology
Pardi, N., Hogan, M. J., & Weissman, D. (2020) · Current Opinion in Immunology · doi:10.1016/j.coi.2020.01.008 · Cited by 512 · cited 1×
“Synthetic biology and biochemical approaches have been used to increase the intracellular stability of vaccine RNAs, reduce cytotoxicity, and enhance protein production (Jackson et al., 2020b; Pardi et al., 2020; Kowalski et al., 2019).”
MethodVogel, A. B., Lambert, L., Kinnear, E., Busse, D., Erbar, S., Reuter, K. C., Wicke, L., Perkovic, M., Beissert, T., Haas, H., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.11.017 · Cited by 501
The promise of mRNA vaccines: a biotech and industrial perspective
Jackson, N. A. C., Kester, K. E., Casimiro, D., Gurunathan, S., & DeRosa, F. (2020) · npj Vaccines · doi:10.1038/s41541-020-0159-8 · Cited by 498 · cited 1×
“Synthetic biology and biochemical approaches have been used to increase the intracellular stability of vaccine RNAs, reduce cytotoxicity, and enhance protein production (Jackson et al., 2020b; Pardi et al., 2020; Kowalski et al., 2019).”
MethodChemically induced proximity in biology and medicine
Stanton, B. Z., Chory, E. J., & Crabtree, G. R. (2018) · Science · doi:10.1126/science.aao5902 · Cited by 475 · cited 1×
“Greater control using kill switches and activity switches Several synthetic biology strategies have been developed to improve the safety of cell therapies, including drug-inducible safety switches (Stanton et al., 2018).”
BackgroundProgramming self-organizing multicellular structures with synthetic cell-cell signaling
Toda, S., Blauch, L. R., Tang, S. K. Y., Morsut, L., & Lim, W. A. (2018) · Science · doi:10.1126/science.aat0271 · Cited by 470
McKay, P. F., Hu, K., Blakney, A. K., Samnuan, K., Brown, J. C., Penn, R., Zhou, J., Bouton, C. R., Rogers, P., Polra, K., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17409-9 · Cited by 462 · cited 2×
“Arcturus and Duke-National University of Singapore (Ramaswamyetal., 2017) and ImperialCollege (McKay et al., 2020) both have phase I clinical trials (NCT04480957, ISRCTN17072692) testing saRNAs expressing pre-fusion-stabilized SARS-CoV-2 spike protein delivered via lipid NPs.”
BackgroundMassively parallel Cas13 screens reveal principles for guide RNA design
Wessels, H.-H., Méndez-Mancilla, A., Guo, X., Legut, M., Daniloski, Z., & Sanjana, N. E. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0456-9 · Cited by 418
Orlandini von Niessen, A. G., Poleganov, M. A., Rechner, C., Plaschke, A., Kranz, L. M., Fesser, S., Diken, M., Löwer, M., Vallazza, B., Beissert, T., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2018.12.011 · Cited by 365 · cited 1×
“Other engineered alterations to RNA structure include the addition of modular 50 untranslated regions (UTRs) and 30 UTRs identified through high-throughput functional screening to stabilize mRNAs and increase protein translation (Orlandini von Niessen et al., 2019; Thess et al., 2015).”
BackgroundDevarkar, S. C., Wang, C., Miller, M. T., Ramanathan, A., Jiang, F., Khan, A. G., Patel, S. S., & Marcotrigiano, J. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1515152113 · Cited by 357
Systemic delivery of factor IX messenger RNA for protein replacement therapy
Ramaswamy, S., Tonnu, N., Tachikawa, K., Limphong, P., Vega, J. B., Karmali, P. P., Chivukula, P., & Verma, I. M. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1619653114 · Cited by 301
Live attenuated influenza virus vaccines by computer-aided rational design
Mueller, S., Coleman, J. R., Papamichail, D., Ward, C. B., Nimnual, A., Futcher, B., Skiena, S., & Wimmer, E. (2010) · Nature Biotechnology · doi:10.1038/nbt.1636 · Cited by 275
A trans-amplifying RNA vaccine strategy for induction of potent protective immunity
Beissert, T., Perkovic, M., Vogel, A., Erbar, S., Walzer, K. C., Hempel, T., Brill, S., Haefner, E., Becker, R., Türeci, Ö., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.09.009 · Cited by 212
Engineering Microbial Living Therapeutics: The Synthetic Biology Toolbox
Pedrolli, D. B., Ribeiro, N. V., Squizato, P. N., de Jesus, V. N., Cozetto, D. A., Tuma, R. B., Gracindo, A., Cesar, M. B., Freire, P. J. C., da Costa, A. F. M., et al. (2019) · Trends in Biotechnology · doi:10.1016/j.tibtech.2018.09.005 · Cited by 189
Tulloch, F., Atkinson, N. J., Evans, D. J., Ryan, M. D., & Simmonds, P. (2014) · eLife · doi:10.7554/elife.04531 · Cited by 178
Modeling metabolism of the human gut microbiome
Magnúsdóttir, S., & Thiele, I. (2018) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2017.12.005 · Cited by 127 · cited 1×
“Modeling the interactions and dynamics of bacteria and metabolites in the human gut has shed light on how dysbiosis promotes disease (Kumar et al., 2019;Magnúsdóttir and Thiele, 2018).”
BackgroundZhou, X., Berglund, P., Zhao, H., Liljeström, P., & Jondal, M. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.7.3009 · Cited by 115 · cited 1×
“, 2015), which are made using parts of alphaviruses such as Semliki Forest virus (Zhou et al., 1995) and Sindbis virus (Herweijer et al.”
MethodLarge-scale recoding of an arbovirus genome to rebalance its insect versus mammalian preference
Shen, S. H., Stauft, C. B., Gorbatsevych, O., Song, Y., Ward, C. B., Yurovsky, A., Mueller, S., Futcher, B., & Wimmer, E. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1502864112 · Cited by 99
New Vaccine Design and Delivery Technologies
Kanekiyo, M., Ellis, D., & King, N. P. (2019) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiy745 · Cited by 69
Cited by
de Puig, H., Lee, R. A., Najjar, D., Tan, X., Soenksen, L. R., Angenent-Mari, N. M., Donghia, N. M., Weckman, N. E., Ory, A., Ng, C. F., et al. (2021) · Science Advances · doi:10.1126/sciadv.abh2944 · Cited by 325
Self-citationTherapeutic reversal of Huntington’s disease by in vivo self-assembled siRNAs
Zhang, L., Wu, T., Shan, Y., Li, G., Ni, X., Chen, X., Hu, X., Lin, L., Li, Y., Guan, Y., et al. (2021) · Brain · doi:10.1093/brain/awab354 · Cited by 97
Contreras-Salgado, E. A., Sánchez-Morán, A. G., Rodríguez-Preciado, S. Y., Sifuentes-Franco, S., Rodríguez-Rodríguez, R., Macías-Barragán, J., & Díaz-Zaragoza, M. (2024) · Microbiology Research · doi:10.3390/microbiolres15030113 · Cited by 42
AI-directed gene fusing prolongs the evolutionary half-life of synthetic gene circuits
(2025) · doi:10.1126/sciadv.adx0796 · Cited by 4
Metadata
- Authors
- Tan, X., Letendre, J. H., Collins, J. J., & Wong, W. W.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2021-02
- Volume
- 184
- Issue
- 4
- Pages
- 881-898
- ISSN
- 0092-8674 (ISSN-L)
- OpenAlex
- W3127382584
- Cited by
- 131
- References
- 48
- FWCI
- 5.03
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.